- Home
- WTI vs ENGN Comparison
WTI vs ENGN Comparison
Compare WTI & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTI
- ENGN
- Stock Information
- Founded
- WTI 1983
- ENGN 1999
- Country
- WTI United States
- ENGN Canada
- Employees
- WTI N/A
- ENGN N/A
- Industry
- WTI Oil & Gas Production
- ENGN
- Sector
- WTI Energy
- ENGN
- Exchange
- WTI Nasdaq
- ENGN Nasdaq
- Market Cap
- WTI 257.9M
- ENGN 297.7M
- IPO Year
- WTI 2005
- ENGN N/A
- Fundamental
- Price
- WTI $1.47
- ENGN $4.44
- Analyst Decision
- WTI Strong Buy
- ENGN Buy
- Analyst Count
- WTI 1
- ENGN 9
- Target Price
- WTI $7.80
- ENGN $25.22
- AVG Volume (30 Days)
- WTI 1.0M
- ENGN 27.4K
- Earning Date
- WTI 05-09-2025
- ENGN 03-10-2025
- Dividend Yield
- WTI 2.73%
- ENGN N/A
- EPS Growth
- WTI N/A
- ENGN N/A
- EPS
- WTI N/A
- ENGN N/A
- Revenue
- WTI $525,260,999.00
- ENGN N/A
- Revenue This Year
- WTI $6.42
- ENGN N/A
- Revenue Next Year
- WTI N/A
- ENGN N/A
- P/E Ratio
- WTI N/A
- ENGN N/A
- Revenue Growth
- WTI N/A
- ENGN N/A
- 52 Week Low
- WTI $1.30
- ENGN $4.00
- 52 Week High
- WTI $2.84
- ENGN $17.10
- Technical
- Relative Strength Index (RSI)
- WTI 38.47
- ENGN 36.32
- Support Level
- WTI $1.58
- ENGN $4.00
- Resistance Level
- WTI $1.68
- ENGN $5.00
- Average True Range (ATR)
- WTI 0.06
- ENGN 0.46
- MACD
- WTI -0.01
- ENGN -0.03
- Stochastic Oscillator
- WTI 17.31
- ENGN 27.50
About WTI W&T Offshore Inc.
W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.